1-6 of 6
Mitsuo Hori, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Daisuke Kudo, MD, Takuya Komeno, MD MPH, PhD, Chikashi Yoshida, MD PhD, Ikuyo Ota Tsutsumi, MD, Kazuteru Ohashi, MD PhD, Kazuhiko Kakihana, MD PhD, Takeshi Kobayashi, MD, Noriko Doki, MD PhD, Yuho Najima, MD, Aiko Igarashi, MD, Mitsuo Hori, MD PhD, Yasushi Okoshi, MD PhD, Takayuki Fujio, MD, Atsushi Shinagawa, MD PhD, Masahide Yamamoto, MD PhD, Hina Takano, MD PhD, Takashi Kumagai, MD PhD, Koh Yamamoto, MD PhD, Shigeo Toyota, MD PhD, Yuichi Nakamura, MD PhD, Hiroshi Kojima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2160.
https://doi.org/10.1182/blood-2018-99-113788
Published: 2018
Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo
Journal: Blood
Blood (2017) 130 (Supplement 1): 434.
https://doi.org/10.1182/blood.V130.Suppl_1.434.434
Published: 2017
Journal Articles

Comprehensive Analysis of Serum Cytokines/Chemokines in Myeloma Patients for Pursuing the Abnormality in Microenvironment and Predicting the Prognosis

Yukiko Cho, PhD, Katsushige Inada, PhD, Yasushi Okoshi, MD PhD, Mitsuo Hori, MD PhD, Hiroshi Kojima, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2083.
https://doi.org/10.1182/blood.V128.22.2083.2083
Published: 2016
Journal Articles

Availability of Circulating microRNAs As a Biomarker for the Early Diagnosis of Diffuse Large B-Cell Lymphoma

Katsushige Inada, PhD, Yasushi Okoshi, MD PhD, Yukiko Cho, PhD, Hitoaki Saito, MD PhD, Tatsuo Iijima, MD PhD, Mitsuo Hori, MD PhD, Hiroshi Kojima, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2988.
https://doi.org/10.1182/blood.V124.21.2988.2988
Published: 2014
Journal Articles

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Chikashi Yoshida, MD, PhD, Takuya Komeno, MD, MPH, PhD, Mitsuo Hori, MD, PhD, Tomofumi Kimura, MD, PhD, Masami Fujii, MD, PhD, Yasushi Okoshi, MD, PhD, Kazumi Suzukawa, MD, PhD, Shigeru Chiba, MD, PhD, Yuichi Hasegawa, MD, PhD, Harumi Yamamoto Mukai, MD, PhD, Takayoshi Ito, MD, PhD, Seiichi Shimizu, MD, PhD, Masaharu Kamoshita, MD, PhD, Daisuke Kudo, MD, Atsushi Shinagawa, MD, PhD, Norio Chikatsu, MD, PhD, Yuriko Monma, MD, Norimichi Watanabe, MD, PhD, Hiroshi Kojima, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1112.
https://doi.org/10.1182/blood.V114.22.1112.1112
Published: 2009